胰高血糖素样肽-1受体激动剂:整形与重建外科医生的实用概述
本文综述了GLP-1受体激动剂(包括艾塞那肽、利拉鲁肽、度拉糖肽、司美格鲁肽和替尔泊肽)在整形外科中的应用。研究显示其可改善血糖控制和减重,可能扩大手术适应证并影响淋巴水肿风险,但需关注胃肠道副作用、胰腺炎、肠梗阻及围手术期误吸风险。
要点
- GLP-1受体激动剂通过促进胰岛素释放、抑制胰高血糖素分泌和增强葡萄糖代谢来管理2型糖尿病。
- Meta分析显示高剂量司美格鲁肽(2 mg)和替尔泊肽(15 mg)可显著降低血红蛋白A1C水平。
- 在整形外科中,其减重和血糖控制效果可能影响围手术期管理,扩大自体皮瓣乳房重建等手术的适应证。
核心结论
- GLP-1受体激动剂在整形外科患者的围手术期体重管理和血糖控制方面具有优势,可能扩大手术适应证并降低淋巴水肿风险,但需仔细考虑并发症,尤其是围手术期误吸风险。
- 未来研究应关注其对手术结局的具体影响,以优化围手术期方案整合。
研究设计与样本
- comprehensive review,分析相关研究、Meta分析和试验,评估GLP-1受体激动剂在手术背景下的获益和局限性。
主要发现
- GLP-1受体激动剂的应用范围涵盖体重管理、心血管健康、神经系统疾病和代谢功能障碍相关肝病。
- Meta分析显示血红蛋白A1C水平显著降低,尤其是高剂量司美格鲁肽(2 mg)和替尔泊肽(15 mg)。
- 增加剂量可能导致胃肠道副作用和胰腺炎、肠梗阻等严重并发症。
- GLP-1受体激动剂在减重和血糖控制方面的疗效可能影响整形外科围手术期管理,可能扩大自体皮瓣乳房重建等手术的适应证,并影响淋巴水肿相关结局。
- 静脉血栓栓塞和胃排空延迟的担忧持续存在,需要进一步研究麻醉期间的出血和误吸风险。
临床怎么用
- GLP-1受体激动剂可能扩大手术适应证并降低淋巴水肿风险,但需仔细考虑并发症,尤其是围手术期误吸风险。
局限性
- 关于静脉血栓栓塞和胃排空延迟的担忧持续存在,需要进一步研究麻醉期间的出血和误吸风险。
- 未来研究应关注GLP-1受体激动剂对手术结局的具体影响,以优化其整合到围手术期方案中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glucagon-like peptide-1 (GLP-1) agonists, such as exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide, effectively manage type 2 diabetes by promoting insulin release, suppressing glucagon secretion, and enhancing glucose metabolism. They also aid weight reduction and cardiovascular health, potentially broadening their therapeutic scope. In plastic surgery, they hold promise for perioperative weight management and glycemic control, potentially impacting surgical outcomes. METHODS: A comprehensive review was conducted to assess GLP-1 agonists' utilization in plastic surgery. We analyzed relevant studies, meta-analyses, and trials to evaluate their benefits and limitations across surgical contexts, focusing on weight reduction, glycemic control, cardiovascular risk factors, and potential complications. RESULTS: Studies demonstrate GLP-1 agonists' versatility, spanning weight management, cardiovascular health, neurological disorders, and metabolic dysfunction-associated liver diseases. Comparative analyses highlight variations in glycemic control, weight loss, and cardiometabolic risk. Meta-analyses reveal significant reductions in hemoglobin A1C levels, especially with high-dose semaglutide (2 mg) and tirzepatide (15 mg). However, increased dosing may lead to gastrointestinal side effects and serious complications like pancreatitis and bowel obstruction. Notably, GLP-1 agonists' efficacy in weight reduction and glycemic control may impact perioperative management in plastic surgery, potentially expanding surgical candidacy for procedures like autologous flap-based breast reconstruction and influencing outcomes related to lymphedema. Concerns persist regarding venous thromboembolism and delayed gastric emptying, necessitating further investigation into bleeding and aspiration risk with anesthesia. CONCLUSIONS: GLP-1 agonists offer advantages in perioperative weight management and glycemic control in plastic surgery patients. They may broaden surgical candidacy and mitigate lymphedema risk but require careful consideration of complications, particularly perioperative aspiration risk. Future research should focus on their specific impacts on surgical outcomes to optimize their integration into perioperative protocols effectively. Despite challenges, GLP-1 agonists promise to enhance surgical outcomes and patient care in plastic surgery.
引用
- Stanton EW, Manasyan A, Banerjee R, et al. Glucagon-Like Peptide-1 Agonists: A Practical Overview for Plastic and Reconstructive Surgeons. Ann Plast Surg. 2024. PMID: 39293069. doi:10.1097/SAP.0000000000004089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。